Navigation Links
Dennis Winger Joins Nektar Therapeutics' Board of Directors
Date:12/14/2009

SAN CARLOS, Calif., Dec. 14 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that Dennis Winger has been appointed to serve on its board of directors. Winger is a highly-respected biopharmaceutical industry leader with over 35 years of experience in corporate management, financial and business strategy.

"Dennis brings to Nektar extensive industry perspective at an important time in the company's evolution," said Howard W. Robin, President and CEO of Nektar and member of the Board of Directors. "As we continue to advance our pipeline, the experience and guidance of leaders like Dennis will be important to Nektar's continued success."

Mr. Winger, 62, is currently a director of Vertex Pharmaceuticals, Cephalon Inc. and Accuray Inc. He retired in 2008 from Applera Corporation, a life sciences company, where he was senior vice president and chief financial officer. Previously, Mr. Winger was senior vice president of finance, administration and chief financial officer at Chiron Corporation. Before that, Mr. Winger held various financial executive leadership roles with divisions of The Cooper Companies. Mr. Winger has played a significant role in major merger and acquisition, financing and divestiture transactions and in managing process and systems growth within accounting, finance and treasury functions. He holds an MBA from Columbia University Graduate School of Business and he earned his undergraduate degree from Siena College.

"Nektar's broadly-applicable polymer conjugate technology is among the most exciting drug development platforms in the biopharmaceutical industry," Winger said. "I look forward to working with Howard and his executive team as they advance the company's strategic business objectives and build the clinical pipeline."

Nektar also announced today that Michael Brown has retired from its Board of Directors effective December 8, 2009. Mr. Brown was a member of Nektar's Board of Directors since 2002. The Board of Directors and the Company wish to recognize the significant contributions that Mr. Brown has made over the past seven years.

"I have enjoyed working with Mike as both a colleague and advisor," said Robin. "On behalf of the entire Board and the Company, we extend our gratitude to Mike for his outstanding contributions to Nektar."

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for leading biopharmaceutical company partners, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia. Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. Nektar is also currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. Nektar recently entered into an exclusive worldwide license agreement with AstraZeneca for its oral NKTR-118 program to treat opioid-induced constipation and its NKTR-119 program for the treatment of pain without constipation side effects. NKTR-102, PEGylated irinotecan, is currently being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Contact: Jennifer Ruddock, 650-631-4954

SOURCE Nektar Therapeutics


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Octapharma Names Dennis D. Curtin To Lead U.S. Plasma Operations
2. Orexigen(R) Therapeutics Appoints Dennis Kim, M.D., as Senior Vice President, Head of Obesity and Metabolic Disorders
3. Fight Melanoma, With Joe Pesci and Dennis Haysbert on Monday, April 21st
4. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
5. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
6. Insmed Appoints Dennis M. Lanfear to Board Of Directors
7. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
8. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
9. Rosalie Dunn, Ph.D., Joins Gwathmey, Inc. as Chief Executive Officer
10. Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner
11. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... ... support for Connecticut's innovative, growing companies, today announced the launch of VentureClash ... technology (fintech) companies. , “VentureClash looks to attract the best early-stage ...
(Date:4/27/2016)... ... April 27, 2016 , ... Cambridge Semantics, the ... technology, today announced that it has been named to The Silicon Review’s “20 Fastest ... and other markets, Cambridge Semantics serves the needs of end users facing some of ...
(Date:4/27/2016)... Columbia , April 27, 2016 ... "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... Anschluss an ihre Pressemitteilung vom 13. August 2015 ... hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten auf ... Kanadische Dollar zu bringen. Davon wurden 157.900.000 Einheiten ...
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, Inc., ... Advisory Board. Dr. Lamka will assist PathSensors in expanding the use of the ... deploys the CANARY® test platform for the detection of harmful pathogens, including a ...
Breaking Biology Technology:
(Date:3/17/2016)... 2016 ABI Research, the leader in ... biometrics market will reach more than $30 billion ... 2015. Consumer electronics, particularly smartphones, continue to boost ... to reach two billion shipments by 2021 at ... , Research Analyst at ABI Research. "Surveillance is ...
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... ) - --> - Renvoi : image ... --> --> ... biométriques, fournit de nouveaux lecteurs d,empreintes digitales pour ... de DERMALOG sera utilisé pour produire des cartes ...
(Date:3/10/2016)... 2016   Unisys Corporation (NYSE: UIS ) ... (CBP) is testing its biometric identity solution at the Otay ... to help identify certain non-U.S. citizens leaving the country. ... to help determine the efficiency and accuracy of using biometric ... will run until May 2016. --> the ...
Breaking Biology News(10 mins):